NCT05689021View on ClinicalTrials.gov

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC V8
Interventions
DRUG

Abiraterone Acetate/Niraparib

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood specimen collection

PROCEDURE

Bone Scan

Undergo technetium-99m bone scan

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Prednisone

Given PO

Trial Locations (3)

32224

RECRUITING

Mayo Clinic in Florida, Jacksonville

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05689021 - CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | Biotech Hunter | Biotech Hunter